- Previous Close
2.6300 - Open
2.6300 - Bid 2.6000 x --
- Ask 2.6400 x --
- Day's Range
2.5700 - 2.6400 - 52 Week Range
2.2100 - 3.3800 - Volume
13,041 - Avg. Volume
29,133 - Market Cap (intraday)
209.777M - Beta (5Y Monthly) 0.89
- PE Ratio (TTM)
21.83 - EPS (TTM)
0.1200 - Earnings Date Feb 26, 2025 - Mar 3, 2025
- Forward Dividend & Yield 0.04 (1.52%)
- Ex-Dividend Date May 17, 2024
- 1y Target Est
--
Laboratorio Reig Jofre, S.A., a pharmaceutical company, engages in the research, development, manufacture, and marketing of pharmaceutical products and specialties, as well as accessories authorized foodstuffs, dietary and personal care products, and cosmetics. The company offers nutritional and parapharmacy products. Its products also include pharmaceutical technologies products, such as antibiotics, and injectables and other products; specialty pharmacare products, which include skin, hair, nails, joint health and pain, and women's health; and food supplements under the Forté Pharma brand. In addition, the company provides CDMO and CMO services; and management and administration services. It sells its products through business partners. The company was founded in 1929 and is headquartered in Barcelona, Spain. Laboratorio Reig Jofre, S.A. operates as a subsidiary of Reig Jofre Investments SL.
www.reigjofre.com1,331
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: RJF.MC
View MorePerformance Overview: RJF.MC
Trailing total returns as of 1/9/2025, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: RJF.MC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: RJF.MC
View MoreValuation Measures
Market Cap
210.58M
Enterprise Value
265.35M
Trailing P/E
22.16
Forward P/E
14.62
PEG Ratio (5yr expected)
0.66
Price/Sales (ttm)
0.63
Price/Book (mrq)
0.99
Enterprise Value/Revenue
0.80
Enterprise Value/EBITDA
7.16
Financial Highlights
Profitability and Income Statement
Profit Margin
2.86%
Return on Assets (ttm)
2.55%
Return on Equity (ttm)
4.61%
Revenue (ttm)
333.69M
Net Income Avi to Common (ttm)
9.55M
Diluted EPS (ttm)
0.1200
Balance Sheet and Cash Flow
Total Cash (mrq)
10.6M
Total Debt/Equity (mrq)
30.93%
Levered Free Cash Flow (ttm)
--